Cargando…

A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)

BACKGROUND: BRCA1/2-related metastatic breast cancers (mBC) are sensitive to DNA-damage agents and show high tumor-infiltrated lymphocytes. We hypothesized that the association between pembrolizumab and carboplatin could be active in BRCA-related mBC. PATIENTS AND METHODS: In this phase II Simon’s d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortesi, L., Venturelli, M., Cortesi, G., Caggia, F., Toss, A., Barbieri, E., De Giorgi, U., Guarneri, V., Musolino, A., De Matteis, E., Zambelli, A., Bisagni, G., Dominici, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163155/ https://www.ncbi.nlm.nih.gov/pubmed/37028000 http://dx.doi.org/10.1016/j.esmoop.2023.101207

Ejemplares similares

Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies
por: Toss, Angela, et al.
Publicado: (2019)

Personalized Systemic Therapies in Hereditary Cancer Syndromes
por: Mastrodomenico, Luciana, et al.
Publicado: (2023)

Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?
por: Cortesi, Laura, et al.
Publicado: (2021)

BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees
por: Cortesi, Laura, et al.
Publicado: (2021)

The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation
por: Toss, Angela, et al.
Publicado: (2016)

Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
por: Toss, Angela, et al.
Publicado: (2021)

Breast ultrasound in high-risk women
por: Cortesi, Laura, et al.
Publicado: (2019)

Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report
por: Cortesi, Laura, et al.
Publicado: (2022)

Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA
por: Piombino, Claudia, et al.
Publicado: (2020)

Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk
por: Tenedini, Elena, et al.
Publicado: (2022)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
por: Toss, Angela, et al.
Publicado: (2022)

BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy
por: Toss, Angela, et al.
Publicado: (2020)

Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes
por: Toss, Angela, et al.
Publicado: (2015)

Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?
por: Toss, Angela, et al.
Publicado: (2017)

Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era
por: Toss, A., et al.
Publicado: (2021)

BRCA mutation carriers’ perceptions on postmenopausal hormone therapy: An Italian study
por: Grandi, Giovanni, et al.
Publicado: (2021)

Ovarian Cancer: Can Proteomics Give New Insights for Therapy and Diagnosis?
por: Toss, Angela, et al.
Publicado: (2013)

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
por: Omarini, Claudia, et al.
Publicado: (2020)

The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study
por: Toss, Angela, et al.
Publicado: (2021)

Lifestyle Intervention on Body Weight and Physical Activity in Patients with Breast Cancer Can Reduce the Risk of Death in Obese Women: The EMILI Study
por: Cortesi, Laura, et al.
Publicado: (2020)

Male mammary myofibroblastoma: Two case reports and brief review of literature
por: Venturelli, Marta, et al.
Publicado: (2020)

COVID-related disruption in mammographic screening: a year later
por: Toss, A., et al.
Publicado: (2022)

Carboplatin/pembrolizumab/pemetrexed: COVID-19 pneumonia: case report
Publicado: (2021)

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer
por: Viansone, A., et al.
Publicado: (2022)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
por: Velcheti, Vamsidhar, et al.
Publicado: (2021)

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions
por: Moon, D H, et al.
Publicado: (2013)

The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life
por: Grandi, Giovanni, et al.
Publicado: (2015)

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
por: Vollebergh, Marieke A, et al.
Publicado: (2014)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Host Cell Reactivation and Transcriptional Activation of Carboplatin-Modified BRCA1
por: Ratanaphan, Adisorn, et al.
Publicado: (2014)

Management of PALB2‐associated breast cancer: A literature review and case report
por: Toss, Angela, et al.
Publicado: (2023)

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
por: Liao, John B, et al.
Publicado: (2021)

Detection of germline BRCA1 mutations by Multiple-Dye Cleavase Fragment Length Polymorphism (MD-CFLP) method
por: Casadei, S, et al.
Publicado: (2001)

BRCA1 and BRCA2 mutations in central and southern Italian patients
por: Ottini, Laura, et al.
Publicado: (2000)

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies
por: Russo, A., et al.
Publicado: (2022)

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
por: O’Brien, Mary E. R., et al.
Publicado: (2018)

Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer
por: Abreu de Oliveira, Willy Antoni, et al.
Publicado: (2021)

Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe
por: Moscetti, L., et al.
Publicado: (2021)

BRCA1 and BRCA2 Gene Mutations in Breast/Ovarian Cancer Patients from Central and Southern Italy
por: Ottini, Laura, et al.
Publicado: (1999)

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
por: Isakoff, Steven J, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_oh36njnkopn9ck5m1u2e8d5g2e